These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 17909047

  • 1. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.
    Buchanan FG, Holla V, Katkuri S, Matta P, DuBois RN.
    Cancer Res; 2007 Oct 01; 67(19):9380-8. PubMed ID: 17909047
    [Abstract] [Full Text] [Related]

  • 2. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2003 Apr 01; 9(4):1566-72. PubMed ID: 12684433
    [Abstract] [Full Text] [Related]

  • 3. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
    Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR, Shin DM.
    Clin Cancer Res; 2005 Sep 01; 11(17):6261-9. PubMed ID: 16144930
    [Abstract] [Full Text] [Related]

  • 4. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
    Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM.
    Clin Cancer Res; 2004 Sep 01; 10(17):5930-9. PubMed ID: 15355926
    [Abstract] [Full Text] [Related]

  • 5. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
    Lal G, Ash C, Hay K, Redston M, Kwong E, Hancock B, Mak T, Kargman S, Evans JF, Gallinger S.
    Cancer Res; 2001 Aug 15; 61(16):6131-6. PubMed ID: 11507063
    [Abstract] [Full Text] [Related]

  • 6. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, Tuccillo C, Vecchione L, Capasso A, Orditura M, De Vita F, Eckhardt SG, Santoro M, Berrino L, Ciardiello F.
    Clin Cancer Res; 2010 Oct 15; 16(20):4990-5001. PubMed ID: 20810384
    [Abstract] [Full Text] [Related]

  • 7. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 8. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 9. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
    Park JS, Jun HJ, Cho MJ, Cho KH, Lee JS, Zo JI, Pyo H.
    Clin Cancer Res; 2006 Aug 15; 12(16):4989-99. PubMed ID: 16914589
    [Abstract] [Full Text] [Related]

  • 10. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, Chinnaiyan AM, Harari PM.
    Cancer Res; 2005 Apr 15; 65(8):3328-35. PubMed ID: 15833866
    [Abstract] [Full Text] [Related]

  • 11. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS, Davis TW, Ornberg RL, Masferrer JL.
    Cancer Res; 2002 Nov 15; 62(22):6706-11. PubMed ID: 12438270
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M, Tsuji S, Tsujii M, Irie T, Komori M, Kimura A, Nishida T, Kakiuchi Y, Kawai N, Murata H, Horimoto M, Sasaki Y, Hayashi N, Kawano S, Hori M.
    Cancer Res; 2003 Oct 15; 63(20):6726-34. PubMed ID: 14583467
    [Abstract] [Full Text] [Related]

  • 13. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
    Narayanan BA, Reddy BS, Bosland MC, Nargi D, Horton L, Randolph C, Narayanan NK.
    Clin Cancer Res; 2007 Oct 01; 13(19):5965-73. PubMed ID: 17908994
    [Abstract] [Full Text] [Related]

  • 14. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
    Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, Sebastiani V, Maitra A, Hidalgo M.
    Cancer Res; 2005 Apr 15; 65(8):3003-10. PubMed ID: 15833824
    [Abstract] [Full Text] [Related]

  • 15. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
    Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J, Buckingham L, Kaiser K, Basu S, Bonomi P.
    Clin Cancer Res; 2008 Apr 01; 14(7):2088-94. PubMed ID: 18381949
    [Abstract] [Full Text] [Related]

  • 16. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.
    Qin J, Yuan J, Li L, Liu H, Qin R, Qin W, Chen B, Wang H, Wu K.
    Biomed Pharmacother; 2009 Mar 01; 63(3):241-8. PubMed ID: 18617357
    [Abstract] [Full Text] [Related]

  • 17. AEE788 potentiates celecoxib-induced growth inhibition and apoptosis in human colon cancer cells.
    Venkatesan P, Bhutia SK, Singh AK, Das SK, Dash R, Chaudhury K, Sarkar D, Fisher PB, Mandal M.
    Life Sci; 2012 Oct 22; 91(15-16):789-99. PubMed ID: 22922496
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
    Choe MS, Chen Z, Klass CM, Zhang X, Shin DM.
    Clin Cancer Res; 2007 May 15; 13(10):3015-23. PubMed ID: 17505004
    [Abstract] [Full Text] [Related]

  • 19. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
    Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3381-8. PubMed ID: 16740761
    [Abstract] [Full Text] [Related]

  • 20. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
    Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA.
    Cancer Res; 2000 Sep 15; 60(18):5040-4. PubMed ID: 11016626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.